Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclizumab vs ATG for Cytopenia in MDS
NCT00072969Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Nov 2003
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daclizumab in myelodysplastic syndrome (MDS), sponsored by National Heart, Lung, and Blood Institute. Started Nov 2003; status: completed.
02
Drugs
daclizumab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00072969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072969.